Vertaling van "other definitions of suicide that have " (Nederlands → Frans) :

We will not dwell on the other definitions of suicide that have been provided by these different disciplines, but will look at one, viz. the one given by Baechler (Baechler, 1975), which goes as follows: “Suicide denotes all behaviour that seeks and finds the solution to an existential problem by making an attempt on the life of the subject”.
Mais nous en retiendrons une, celle de Baechler (Baechler, 1975): « le suicide désigne tout comportement qui cherche et qui trouve la solution d’un problème existentiel dans le fait d’attenter à la vie du sujet ».

In contrast to what is the case in many other definitions of suicide, the author refers to suicide as a type of behaviour and not as an act.
Dans cette définition du suicide, contrairement à beaucoup d’autres, l’auteur parle de comportement et non d’acte.

Analysis by region Attempted suicides, both those that have been committed sometime during one’s existence and those that have been committed recently, are less frequent in the Flemish region (2% and 0,3% respectively) than in the other two regions (6% and 0,6% in each of the other regions, respectively).
Analyse par régions: Les tentatives de suicide , que ce soit au cours de la vie ou commises récemment au moment de l’enquête sont moins fréquentes en région flamande (2 % et 0,3 % respectivement) que dans les deux autres régions (6 % et 0,6 % respectivement dans chacune des régions).

Imperfect though it may be, it was interesting to have another look at Baechler’s definition that treats suicide as all behaviour that seeks and finds the solution to an existential problem by making an attempt on the life of the subject. There were several reasons for this:
Malgré les imperfections possibles de la définition de Baechler qui parle du suicide comme tout comportement qui cherche et qui trouve la solution d’un problème existentiel dans le fait d’attenter à la vie du sujet, il était intéressant de la reprendre et cela pour plusieurs raisons:

Likewise, research carried out up to now has shown that there appears to be a definite connection in all countries, both industrial and developing countries, between alcohol consumption (notably in the Russian Federation and the Baltic states), free access to certain toxic substances (e.g. in China, India and Sri Lanka) and firearms (e.g. in El Salvador and the United States) on the one hand, and the rate of suicide on the other.
De même, la consommation d’alcool (notamment en Fédération de Russie et dans les Etats baltes) ainsi que le libre accès à certaines substances toxiques (en Chine, en Inde et au Sri Lanka, par exemple) et aux armes à feu (à El Salvador et aux Etats-Unis d’Amérique, entre autres) semblent, d’après les études réalisées jusqu’à présent, associés de façon certaine aux taux de suicide dans tous les pays, industrialisés ou en développement.

Various studies and experiences have shown that it is absolutely essential that those who have attempted to commit suicide should be received in an appropriate manner, that they should be given adequate care and that there should be an appropriate follow-up once they have been treated in the hospital.
La nécessité de mettre en place un accueil, une prise en charge et un suivi post-hospitalier adéquats des suicidants est apparue fondamentale à travers différentes études et expériences.

Different studies (Cremniter et al.,1998; Lejoyeux et al., 1994; Fawcett et al., 1990) have revealed that suicide is closely related to psychiatric disorders and that generally, depression is the final common stage towards suicide, whatever the disorder.
Divers travaux (Cremniter et al., 1998; Lejoyeux et al., 1994; Fawcett et al. 1990) ont pu montrer que le suicide était étroitement lié aux maladies psychiatriques et que généralement, quel que soit le trouble, la dépression est le chemin final commun vers le suicide.

This release contains forward-looking information about an agreement by Pfizer to acquire FoldRx, and about FoldRx’s product candidate tafamidis, its other clinical and preclinical development programs and its technology platform, including their potential benefits, that involves substantial risks and uncertainties. Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and in its reports on Form 10-Q and Form 8-K.
Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments.

Average Wholesale Price litigation Claims have been brought against various pharmaceutical companies, including NPC and certain Sandoz entities, alleging that they fraudulently overstated the Average Wholesale Price and “best price”, which are, or have been, used by the US federal and state governments in the calculation of, respectively, Medicare reimbursements and Medicaid rebates. In some cases, motions to dismiss or (cross-) motions for summary judgment in other cases have been made and are currently pending.
Litige concernant le prix de gros moyen Des plaintes ont été déposées contre différentes sociétés pharmaceutiques, dont NPC et certaines entités de Sandoz, au motif que celles-ci auraient frauduleusement exagéré le prix de gros moyen (average wholesale price [AWP]) et le «meilleur prix» qui sont ou ont été utilisés par le gouvernement fédéral américain et des gouvernements d’Etat pour calculer les remboursements des médicaments dans le cadre du programme Medicare et les rabais dans celui de Medicaid.

Novartis has several other drugs in its pipeline that have promise for patients with unmet needs.
Novartis possède plusieurs autres médicaments dans son pipeline qui répondent aux besoins non satisfaits des malades.